^
Association details:
| Biomarker: | JAK2 V617F |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fast response and tumor lysis syndrome in patients treated with 5-azacitidine and venetoclax for secondary AML originating from MDS/MPN
Published date:
09/03/2020
Excerpt:
A 72-year old woman was diagnosed with sAML...Molecular analysis identified a new JAK2 V617F mutation….She was started on 5-azacitidine and venetoclax... During the first cycle of the combination she rapidly cleared her PB blasts. Treatment was continued with a second cycle....AML and underlying MDS/MPN reported here showed rapid responses to the combination of 5-azacitidine and venetoclax even with slow ramp-up.
Secondary therapy:
azacitidine
